Abstract
The in vivo application potential of viral-based gene delivery approaches is hindered by a risk of insertional oncogenesis. Of the many delivery methods, cell-penetrating peptides (CPP)-based delivery has good biocompatibility and biodegradability. However, low efficiency is still the disadvantage of CPPs-based nucleic acid transfection, and delivery efficiency may vary from different CPPs. Here, we describe Scp01-b, as a new CPP, which can enter cultured cell lines and primary cultured cells examined by fluorescence microscopy and quantitative assay, the internalization process is a concentration, temperature, and incubation time-dependent manner. Scp01-b does not insert into the membrane directly and its uptake is mediated through endocytosis pathway. Moreover, Scp01-b could mediate the uptake of plasmid DNA into the Caski and HSC-T6 cells, and we noted that Scp01-b-mediated transfection efficiency was nearly the same with traditional liposome (TurboFectin)-mediated transfection. These findings suggest that Scp01-b can act as a useful tool for non-viral-based delivery in further application such as reprogramming and gene editing.
Original language | English (US) |
---|---|
Pages (from-to) | 6539-6547 |
Number of pages | 9 |
Journal | Journal of Cellular Physiology |
Volume | 234 |
Issue number | 5 |
DOIs | |
State | Published - May 2019 |
Externally published | Yes |
Keywords
- cell-penetrating peptide
- drug delivery
- transfection
ASJC Scopus subject areas
- Physiology
- Clinical Biochemistry
- Cell Biology